Home » Stocks » Sol-Gel Technologies

Sol-Gel Technologies Ltd. (SLGL)

Stock Price: $8.18 USD -0.29 (-3.42%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 188.11M
Revenue (ttm) 22.90M
Net Income (ttm) -24.61M
Shares Out 23.00M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $8.18
Previous Close $8.47
Change ($) -0.29
Change (%) -3.42%
Day's Open 8.38
Day's Range 8.16 - 8.38
Day's Volume 8,109
52-Week Range 5.00 - 21.00

More Stats

Market Cap 188.11M
Enterprise Value 139.78M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 23.00M
Float 8.48M
EPS (basic) -1.26
EPS (diluted) -1.33
FCF / Share -1.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 98,972
Short Ratio 7.38
Short % of Float 1.17%
Beta 1.45
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.21
PB Ratio 2.88
Revenue 22.90M
Operating Income -25.95M
Net Income -24.61M
Free Cash Flow -23.10M
Net Cash 48.33M
Net Cash / Share 2.10
Gross Margin -132.38%
Operating Margin -113.30%
Profit Margin -107.40%
FCF Margin -100.84%
ROA -26.55%
ROE -46.79%
ROIC -46.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$20.25*
(147.56% upside)
Low
16.0
Current: $8.18
High
23.0
Target: 20.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue22.900.130.17--
Revenue Growth17655.04%-25.86%---
Gross Profit22.900.130.17--
Operating Income-25.95-33.52-31.63-20.76-9.65
Net Income-24.61-32.20-31.57-20.77-9.66
Shares Outstanding19.5317.876.296.296.29
Earnings Per Share-1.26-1.80-5.02-3.30-1.53
Operating Cash Flow-22.50-23.47-24.09-18.50-8.04
Capital Expenditures-0.60-1.05-1.93-0.39-0.29
Free Cash Flow-23.10-24.52-26.01-18.88-8.34
Cash & Equivalents50.3862.999.027.005.90
Total Debt2.05-65.3437.3417.34
Net Cash / Debt48.3362.99-56.31-30.34-11.44
Assets61.3069.6815.3210.998.24
Liabilities8.845.7768.0142.3219.76
Book Value52.4763.91-52.70-31.34-11.52
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sol-Gel Technologies Ltd.
Country Israel
Employees 61
CEO Alon Seri-Levy

Stock Information

Ticker Symbol SLGL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SLGL
IPO Date January 23, 2018

Description

Sol-Gel Technologies, a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, which has completed Phase II clinical trials for the treatment of acne vulgaris; Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea; SGT-210, a epidermal growth factor receptor inhibitor, which is in development for the treatment of palmoplantar keratoderma and non-melanoma skin cancer; and tapinarof and roflumilast to treat psoriasis and other dermatological indications. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.